Responsiveness to recombinant erythropoietin therapy in end-stage renal disease. An analysis of the predictive value of several biological measurements, including circulating erythroid progenitors.
In end-stage renal disease (ESRD), the human recombinant erythropoietin doses required to keep haemoglobin in the target range may vary considerably between patients. Previous studies have failed to find any predictive factor of the response. We thus performed the present investigation in 30 ESRD patients to discover if the haematological response to human recombinant erythropoietin (rHuEpo) was related to the results of circulating erythroid progenitor cultures. Peripheral erythroid burst forming units (BFU-E) were cultured in a plasma clot system in the absence or in the presence of autologous serum just before starting rHuEpo therapy. The results showed a higher BFU-E number in ESRD patients than in controls and a stimulatory effect of autologous serum in both patients and controls. Comparison between culture results and haematological response yielded positive correlation between the BFU-E number and the haemoglobin increase during the first month of treatment, and negative correlation between the increase of BFU-E numbers during the first week of therapy and the rHuEpo doses required for a long-term response. We thus conclude that in ESRD patients the individual response to rHuEpo is linked to the numbers of circulating BFU-E.